AMLX - Amylyx Pharmaceuticals, Inc.

QQQ $ 612.14 $ 1.56 (0.26 %)

DIA $ 470.45 $ 1.64 (0.35 %)

SPY $ 672.31 $ 2.95 (0.44 %)

TLT $ 89.45 $ -0.19 (-0.21 %)

GLD $ 367.77 $ 0.35 (0.1 %)

Previous Close

$ 12.31

Open

$ 12.56

Bid

$ 11.50 x 10

Ask

$ 14.00 x 6

Day's Range

$ 11.91 - $ 12.56

52 Week Range

$ 2.60 - $ 16.96

Volume

1,901,558

Average Volume

Market Cap

1.35B

Beta (5Y Monthly)

$ 1.18

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-06-2025	09-30-2025	10-Q
2	08-07-2025	06-30-2025	10-Q
3	05-08-2025	03-31-2025	10-Q
4	03-04-2025	01-01-1970	10-K
5	11-07-2024	09-30-2024	10-Q
6	08-08-2024	06-30-2024	10-Q
7	05-09-2024	03-31-2024	10-Q
8	02-22-2024	12-31-2023	10-K
9	11-09-2023	09-30-2023	10-Q
10	08-10-2023	06-30-2023	10-Q
11	05-11-2023	03-31-2023	10-Q
12	03-13-2023	12-31-2022	10-K
13	11-10-2022	09-30-2022	10-Q
14	08-11-2022	06-30-2022	10-Q
15	05-12-2022	03-31-2022	10-Q
16	03-31-2022	12-31-2021	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Maintains Buy on Amyly...
11/07/2025 19:52:34

HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price t...

Amylyx Pharma Q3 EPS $(0.37) Beats $(0.45)...
11/06/2025 12:04:12

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45)...

Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

Citigroup Maintains Buy on Amylyx Pharmace...
10/17/2025 15:21:27

Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $...

Baird Maintains Outperform on Amylyx Pharm...
10/16/2025 11:30:20

Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from ...

B of A Securities Maintains Buy on Amylyx ...
10/03/2025 13:06:10

B of A Securities analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price targe...

Goldman Sachs Maintains Buy on Amylyx Phar...
09/16/2025 16:41:28

Goldman Sachs analyst Corinne Johnson maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target ...

Guggenheim Maintains Buy on Amylyx Pharmac...
09/15/2025 12:33:07

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target fr...

Amylyx Pharmaceuticals Prices $175M Underw...
09/10/2025 06:23:50

Amylyx Pharmaceuticals Announces An Underw...
09/09/2025 20:03:25

Amylyx Pharmaceuticals (NASDAQ:AMLX) Has Initiated An Underwritten Public Offering Of Its Common Stock, With All Shares Being O...

Reported Earlier: 'Amylyx's Withdrawn-From...
08/28/2025 16:09:12

https://www.fiercebiotech.com/biotech/amylyx-axes-rare-disease-program-after-relyvrio-fails-beat-placebo#:~:text=Amylyx%20axes%...

B of A Securities Maintains Buy on Amylyx ...
08/28/2025 15:47:56

B of A Securities analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price targe...

'FDA Withdrawing Approval Of NDA For Relyv...
08/28/2025 13:10:42

https://www.federalregister.gov/public-inspection/2025-16646/withdrawal-of-approval-of-new-drug-application-amylyx-pharmaceutic...

amylyx-halts-rare-brain-disorder-drug-program-after-disappointing-trial

Amylyx Halts Rare Brain Disorder Drug Prog...
08/27/2025 16:24:53

Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting d...

Amylyx Pharma To Discontinue ORION Program...
08/27/2025 11:15:33

- AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24- AMX0035 continued to be gen...

Amylyx Pharma Q2 EPS $(0.46) Misses $(0.45...
08/07/2025 11:01:04

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.4...

Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

amylyx-drug-slashes-sugar-spikes-post-weight-loss-surgery

Amylyx Drug Slashes Sugar Spikes Post-Weig...
07/14/2025 18:15:11

Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric ...

Reported Sunday, Amylyx Highlights Efficac...
07/14/2025 06:47:50

Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy...

Goldman Sachs Reinstates Buy on Amylyx Pha...
07/10/2025 18:12:58

Goldman Sachs analyst Corinne Johnson reinstates Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and announces $10 price tar...